MEDI-528, now recognized as enokizumab , represents a innovative therapeutic targeting the IGF-1R , a crucial protein implicated in multiple dermatological conditions . Early clinical results suggest https://ammarrcyr174913.mpeblog.com/74084262/enokizumab-a-deep-dive-into-medi-528-and-its-potential